September 7, 2023 10:54 AM EDT
R&D

Val­ne­va and Pfiz­er tout re­sults for the PhII of its Ly­me dis­ease vac­cine

Tyler Patchen

News Reporter

Pfiz­er and Val­ne­va are tout­ing pos­i­tive re­sults in a Phase II tri­al for their Ly­me dis­ease vac­cine can­di­date when it was ad­min­is­tered as a boost­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times